Impact of intravesical onabotulinumtoxinA on sexual function in women with OAB

Urgency urinary incontinence (UUI), and the symptoms of overactive bladder (OAB) have a negative impact on female sexual function. The aim of this study was to investigate the effect of intravesical onabotulinumtoxinA (Botox) injection on sexual function in women with OAB, using the multi domain Female Sexual Function Index (FSFI) questionnaire.

[1]  G. Amarenco,et al.  Les anticholinergiques ne modifient pas la fonction sexuelle chez les patientes atteintes de sclérose en plaques , 2016 .

[2]  S. Kaplan,et al.  The concomitant use of fesoterodine and topical vaginal estrogen in the management of overactive bladder and sexual dysfunction in postmenopausal women , 2016, Post reproductive health.

[3]  S. Musco,et al.  Percutaneous Tibial Nerve Stimulation Improves Female Sexual Function in Women With Overactive Bladder Syndrome. , 2016, The journal of sexual medicine.

[4]  S. Pillay,et al.  Conjoint Urological Society of Australia and New Zealand (USANZ) and Urogynaecological Society of Australasia (UGSA) Guidelines on the management of adult non‐neurogenic overactive bladder , 2016, BJU international.

[5]  G. Amarenco,et al.  [Anticholinergics do not affect the sexual function in women diagnosed with multiple sclerosis]. , 2016, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.

[6]  P. Miotła,et al.  Effectiveness of botulinum toxin injection in the treatment of de novo OAB symptoms following midurethral sling surgery , 2015, International Urogynecology Journal.

[7]  E. Geller,et al.  The effect of sacral neuromodulation on pudendal nerve function and female sexual function , 2015, Neurourology and urodynamics.

[8]  A. Berardelli,et al.  OnabotulinumtoxinA intradetrusorial injections improve sexual function in female patients affected by multiple sclerosis: preliminary results , 2015, World Journal of Urology.

[9]  M. Faraday,et al.  Diagnosis and treatment of overactive bladder (non-neurogenic) in adults: AUA/SUFU guideline amendment. , 2015, The Journal of urology.

[10]  A. Nambiar,et al.  Chapter 4: Guidelines for the diagnosis and treatment of overactive bladder (OAB) and neurogenic detrusor overactivity (NDO) , 2014, Neurourology and urodynamics.

[11]  G. Guyatt,et al.  What Is the Most Bothersome Lower Urinary Tract Symptom? Individual- and Population-level Perspectives for Both Men and Women , 2014, European urology.

[12]  C. Nardo,et al.  OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial. , 2013, European urology.

[13]  Urszula Sioma-Markowska,et al.  Development and validation of the Polish version of the Female Sexual Function Index in the Polish population of females. , 2013, The journal of sexual medicine.

[14]  Xiaohong Yan,et al.  OnabotulinumtoxinA for the treatment of patients with overactive bladder and urinary incontinence: results of a phase 3, randomized, placebo controlled trial. , 2013, The Journal of urology.

[15]  C. Thompson,et al.  The impact of OAB on sexual health in men and women: results from EpiLUTS. , 2011, The journal of sexual medicine.

[16]  G. P. Galatioto,et al.  [Impact of overactive bladder on sexual function in women]. , 2011, Urologia.

[17]  R. Freeman,et al.  An international urogynecological association (IUGA)/international continence society (ICS) joint report on the terminology for female pelvic floor dysfunction , 2010, Neurourology and urodynamics.

[18]  R. Basson,et al.  Summary of the recommendations on sexual dysfunctions in women. , 2010, The journal of sexual medicine.

[19]  K. Coyne,et al.  The impact of overactive bladder, incontinence and other lower urinary tract symptoms on quality of life, work productivity, sexuality and emotional well‐being in men and women: results from the EPIC study , 2008, BJU international.

[20]  J. Rybakowski,et al.  [The study of the prevalence of depressive disorders in primary care patients in Poland]. , 2007, Wiadomosci lekarskie.

[21]  P. Miotła,et al.  [Women's sexual life quality assessment with use of questionnaires in clinical trials--review of accessible tools, their characteristics and comparison of their properties]. , 2005, Ginekologia polska.

[22]  R. Rosen,et al.  The Female Sexual Function Index (FSFI): Cross-Validation and Development of Clinical Cutoff Scores , 2005, Journal of sex & marital therapy.

[23]  Irwin Goldstein,et al.  Summary of the recommendations on sexual dysfunctions in women. , 2004, The journal of sexual medicine.

[24]  Candace S. Brown,et al.  The Female Sexual Function Index (FSFI): a multidimensional self-report instrument for the assessment of female sexual function. , 2000, Journal of sex & marital therapy.

[25]  J. Duckett,et al.  A new questionnaire to assess the quality of life of urinary incontinent women , 1998, British journal of obstetrics and gynaecology.